Meropenem-Vaborbactam

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 334 publications

In vitro susceptibility of Stenotrophomonas maltophilia and other carbapenem non-susceptible Gram-negative rods in the Pacific Northwest to cefiderocol and aztreonam-avibactam.

In vitro susceptibility of Stenotrophomonas maltophilia and other carbapenem non-susceptible Gram-negative rods in the Pacific Northwest to cefiderocol and aztreonam-avibactam.

Journal: JAC-antimicrobial resistance

Published: June 10, 2026

Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World.

Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 02, 2026

Treatment of Post-Neurosurgical Ventriculitis and Scalp Infection Caused by Klebsiella pneumoniae Carbapenemase and New Delhi Metallo-β-Lactamase Co-Producing Carbapenem-Resistant Klebsiella pneumoniae: A Case Report.

Treatment of Post-Neurosurgical Ventriculitis and Scalp Infection Caused by Klebsiella pneumoniae Carbapenemase and New Delhi Metallo-β-Lactamase Co-Producing Carbapenem-Resistant Klebsiella pneumoniae: A Case Report.

Journal: Cureus

Published: May 15, 2026

Risk factors for in vivo emergence of ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae and the associated resistance mechanisms: a case-control study.

Risk factors for in vivo emergence of ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae and the associated resistance mechanisms: a case-control study.

Journal: Microbiology spectrum

Published: May 04, 2026

Innovations in the Treatment of Antibiotic-Resistant Infections in Internal Medicine.

Innovations in the Treatment of Antibiotic-Resistant Infections in Internal Medicine.

Journal: Cureus

Published: April 17, 2026

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.

Journal: Antimicrobial agents and chemotherapy

Published: March 23, 2026

Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.

Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.

Journal: Scientific reports

Published: March 13, 2026

Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.

Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.

Journal: Diagnostics (Basel, Switzerland)

Published: March 10, 2026

In vitro activity of ceftazidime-avibactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, cefiderocol, and plazomicin against non-fermenting Gram-negative isolates obtained from Bulgarian inpatients.

In vitro activity of ceftazidime-avibactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, cefiderocol, and plazomicin against non-fermenting Gram-negative isolates obtained from Bulgarian inpatients.

Journal: Acta microbiologica et immunologica Hungarica

Published: March 10, 2026

In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection.

In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection.

Journal: Antimicrobial agents and chemotherapy

Published: March 05, 2026

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents.

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents.

Journal: Frontiers in microbiology

Published: February 25, 2026

In vitro activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023.

In vitro activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023.

Journal: JAC-antimicrobial resistance

Published: February 21, 2026

Showing 1-12 of 334

Last Updated: 06/30/2026